Loading company
Loading
Latest annual · FY2025
Millions- Total revenues
- 25
- Operating income
- (96)
- Net income
- (88)
Metagenomi Therapeutics, Inc. (MGX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $25.2 million | $52.3 million | -51.8% | 10-K 2026-03-05 · proof |
| Operating income | -$96 million | -$88.9 million | 10-K 2026-03-05 · proof | |
| Net income | -$87.9 million | -$78.1 million | 10-K 2026-03-05 · proof | |
| Cash from operating activities | -$88.9 million | -$109.1 million | 10-K 2026-03-05 · proof | |
| Free cash flow | -$89.5 million | -$112.2 million | 10-K 2026-03-05 · proof | |
| Total assets | $221.1 million | $324.6 million | -31.9% | 10-K 2026-03-05 · proof |
| Total liabilities | $62.5 million | $89.7 million | -30.3% | 10-K 2026-03-05 · proof |
| Cash and cash equivalents | $41.7 million | $27.4 million | +52.3% | 10-K 2026-03-05 · proof |
- What was Metagenomi Therapeutics, Inc. (MGX)'s revenue in fiscal 2025?
- Metagenomi Therapeutics, Inc. (MGX) reported revenue of $25.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $52.3 million the year before (-51.8%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Metagenomi Therapeutics, Inc. (MGX)'s operating income in fiscal 2025?
- Metagenomi Therapeutics, Inc. (MGX) reported operating income of -$96 million for fiscal 2025 (the year ended Dec 31, 2025), against -$88.9 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Metagenomi Therapeutics, Inc. (MGX)'s net income in fiscal 2025?
- Metagenomi Therapeutics, Inc. (MGX) reported net income of -$87.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$78.1 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Metagenomi Therapeutics, Inc. (MGX)'s cash from operating activities in fiscal 2025?
- Metagenomi Therapeutics, Inc. (MGX) reported cash from operating activities of -$88.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$109.1 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Metagenomi Therapeutics, Inc. (MGX)'s free cash flow in fiscal 2025?
- Metagenomi Therapeutics, Inc. (MGX) reported free cash flow of -$89.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$112.2 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What are Metagenomi Therapeutics, Inc. (MGX)'s total assets?
- As of Dec 31, 2025, Metagenomi Therapeutics, Inc. (MGX) reported total assets of $221.1 million, against $324.6 million a year earlier (-31.9%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What are Metagenomi Therapeutics, Inc. (MGX)'s total liabilities?
- As of Dec 31, 2025, Metagenomi Therapeutics, Inc. (MGX) reported total liabilities of $62.5 million, against $89.7 million a year earlier (-30.3%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What are Metagenomi Therapeutics, Inc. (MGX)'s cash and cash equivalents?
- As of Dec 31, 2025, Metagenomi Therapeutics, Inc. (MGX) reported cash and cash equivalents of $41.7 million, against $27.4 million a year earlier (+52.3%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:MGX&period_type=annual&limit=5"Information only, not investment advice.